Summit Therapeutics and Akeso share prices plummet following the FDA’s rejection
Regulatory authority refuses to approve lung cancer drug: Chinese firm falls by up to 32 per cent in Hong Kong, whilst US group drops by up to 12 per cent
Summit Therapeutics and Akeso’s research into cancer immunotherapy has hit a setback in the United States. The Food and Drug Administration (FDA) has rejected, in its current form, the application for authorisation of ivonescimab, the experimental lung cancer drug developed by the two companies. This decision had an immediate impact on the markets: during the trading session on Monday 16 November on the Hong Kong stock exchange, Akeso shares fell by as much as 32 per cent before closing down 22 per cent, whilst Summit Therapeutics shares dropped by as much as 12 per cent at the opening of trading on Wall Street.
At the heart of the US regulator’s decision lies the failure to demonstrate a tangible benefit in terms of patients’ overall survival. According to the FDA, ivonescimab did not achieve a statistically significant improvement in this outcome measure. The drug was shown to slow the progression of the disease, but this result was not considered sufficient to justify its authorisation.
Analysts have also interpreted the rejection as a sign of weakness in the ability of Chinese biotech companies to bring innovative and competitive drugs to the international market that can rival the products of major Western pharmaceutical groups.
Akeso’s disappointment
The backlash has been particularly severe for Akeso. During a conference call with investors, Chief Executive Michelle Xia acknowledged that the trial results had not met the FDA’s requirements in terms of overall survival. However, she emphasised that the company continues to believe in the drug’s potential and regards the decision as an isolated case, rather than a blanket rejection of its research platform.
“This is the most discouraging moment in the 14 years since Akeso was founded,” said Xia, whilst pointing out, however, that the company had passed the inspections carried out by the FDA at its clinical trial centres in China and its manufacturing facilities.


